50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies

Background: Meta10-19, the innovative IL-10 expressing CD19 CAR-T cells, show significant potential in addressing T cell dysfunction, a major hurdle in current CAR-T therapies.This dysfunction often leads to resistance and relapse in patients with relapsed/refractory (r/r) B-cell hematological malignancies.Methods: From February 2023 to July 2024, we enrolled and treated a total of 20 eligible patients with r/r B-cell hematological malignancies, including 10 patients with DLBCL and 10 patients with B-ALL.Patients received a single infusion of Meta10-19 across multiple dose level (DL) cohorts from 2.010 4 cells/kg to 2.010 5 cells/kg.The administration followed a standard lymphodepletion regimen involving 30 mg/m 2 / day fludarabine for 3 days, and 300 mg/m 2 /day cyclophosphamide for 3 days.CRS and ICANS were graded according to Lee 2014 and ASTCT 2019 guidelines, respectively.AEs were assessed based on CTCAE 5.0 criteria.

Authors

Institutions

Publication Details

Journal
Immuno-Oncology Technology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.iotech.2024.100861
Citations
2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.57
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies

Marcela Martínez-Prieto, Devon J. Shedlock, C. Martin, Peter Vu et al.
2 citations
Immuno-Oncology Technology
CAR-T cell therapy research
0.57
article

50P Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies

Marcela Martínez-Prieto, Devon J. Shedlock, C. Martin, Peter Vu, David Bauer, J.C. Baranda, J. Henry, J. Coronella, J. McCaigue, R. Belani, I.I. Rodriguez Rivera, Ann Murphy, David Yoonsuk Oh, E.E. Dumbrava, Susan Haag, H. Namini, J.D. Eskew, Catherine Gregovics
article en
2 citations

Abstract

Background: Meta10-19, the innovative IL-10 expressing CD19 CAR-T cells, show significant potential in addressing T cell dysfunction, a major hurdle in current CAR-T therapies.This dysfunction often leads to resistance and relapse in patients with relapsed/refractory (r/r) B-cell hematological malignancies.Methods: From February 2023 to July 2024, we enrolled and treated a total of 20 eligible patients with r/r B-cell hematological malignancies, including 10 patients with DLBCL and 10 patients with B-ALL.Patients received a single infusion of Meta10-19 across multiple dose level (DL) cohorts from 2.010 4 cells/kg to 2.010 5 cells/kg.The administration followed a standard lymphodepletion regimen involving 30 mg/m 2 / day fludarabine for 3 days, and 300 mg/m 2 /day cyclophosphamide for 3 days.CRS and ICANS were graded according to Lee 2014 and ASTCT 2019 guidelines, respectively.AEs were assessed based on CTCAE 5.0 criteria.

Immuno-Oncology TechnologyVol. 24
The University of Texas MD Anderson Cancer Center (US), Sarah Cannon Research Institute (GB), University of California, San Francisco (US), UC San Diego Health System (US), Sarah Cannon (US), University of Kansas Medical Center (US), Poseida Therapeutics (United States) (US)
Good health and well-being
Openalex Percentile: Top 26%
CAR-T cell therapy research
0.57
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.